CY1113403T1 - Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων - Google Patents

Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων

Info

Publication number
CY1113403T1
CY1113403T1 CY20121100924T CY121100924T CY1113403T1 CY 1113403 T1 CY1113403 T1 CY 1113403T1 CY 20121100924 T CY20121100924 T CY 20121100924T CY 121100924 T CY121100924 T CY 121100924T CY 1113403 T1 CY1113403 T1 CY 1113403T1
Authority
CY
Cyprus
Prior art keywords
monitoring
therapies
assessing
evolution
effectiveness
Prior art date
Application number
CY20121100924T
Other languages
Greek (el)
English (en)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of CY1113403T1 publication Critical patent/CY1113403T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
CY20121100924T 2007-10-24 2012-10-04 Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων CY1113403T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
EP08842581A EP2201376B1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
CY1113403T1 true CY1113403T1 (el) 2016-06-22

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100924T CY1113403T1 (el) 2007-10-24 2012-10-04 Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων
CY20151100234T CY1116089T1 (el) 2007-10-24 2015-03-06 Cd73 ως ενας βιοδεικτης για την παρακολουθηση της εξελιξης νοσων και εκτιμηση της αποτελεσματικοτητας θεραπειων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20151100234T CY1116089T1 (el) 2007-10-24 2015-03-06 Cd73 ως ενας βιοδεικτης για την παρακολουθηση της εξελιξης νοσων και εκτιμηση της αποτελεσματικοτητας θεραπειων

Country Status (14)

Country Link
US (1) US20100209942A1 (enExample)
EP (2) EP2201376B1 (enExample)
JP (2) JP4982610B2 (enExample)
KR (2) KR20160029869A (enExample)
CA (1) CA2702635A1 (enExample)
CY (2) CY1113403T1 (enExample)
DK (2) DK2201376T3 (enExample)
ES (2) ES2532361T3 (enExample)
FI (1) FI20070795A0 (enExample)
HR (2) HRP20120743T1 (enExample)
PL (2) PL2201376T3 (enExample)
PT (2) PT2201376E (enExample)
SI (2) SI2201376T1 (enExample)
WO (1) WO2009053523A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704689XA (en) 2008-01-18 2017-07-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
SG10201505723UA (en) 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
CA2806301A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
MX2013000917A (es) 2010-07-23 2013-07-05 Harvard College Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
EA201590024A1 (ru) 2012-06-15 2015-05-29 Гарри Стилли Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
PL2956772T3 (pl) * 2013-02-14 2018-12-31 Faron Pharmaceuticals Oy Sposób określenia biomarkerów związanych z zespołem ostrej niewydolności oddechowej (ARDS), sposób monitorowania rozwoju i leczenia ARDS u pacjenta
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
EP4428251A3 (en) 2014-09-11 2024-12-18 Immunis.AI, Inc. Methods of detecting prostate cancer
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
GB201706747D0 (en) 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients
GB201715115D0 (en) 2017-09-19 2017-11-01 Univ London Queen Mary Methods for assessing risk of cardiovascular disease and methods and compounds for use in treating or preventing cardiovascular disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007236A1 (en) * 1995-08-18 1997-02-27 Landry Donald W Detection of organic compounds through regulation of antibody-catalyzed reactions
WO1997013875A1 (en) 1995-10-13 1997-04-17 Imperial College Of Science, Technology & Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
CA2439961A1 (en) * 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
US7534423B2 (en) * 2003-03-28 2009-05-19 Faron Pharmaceuticals Oy Method for inducing an elevated level of adenosine in an individual
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
CA2528152A1 (en) * 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
WO2007107598A1 (en) * 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
EP3796002B1 (en) * 2006-07-14 2023-11-22 The Regents of The University of California Cancer biomarkers and methods of use thereof

Also Published As

Publication number Publication date
KR20100059902A (ko) 2010-06-04
JP2012159514A (ja) 2012-08-23
ES2389751T3 (es) 2012-10-31
PL2201376T3 (pl) 2013-01-31
EP2201376A1 (en) 2010-06-30
DK2503338T3 (en) 2015-03-09
PT2503338E (pt) 2015-03-05
JP4982610B2 (ja) 2012-07-25
EP2503338A3 (en) 2013-03-13
EP2201376B1 (en) 2012-08-08
PT2201376E (pt) 2012-08-20
CY1116089T1 (el) 2017-02-08
JP2011501176A (ja) 2011-01-06
SI2503338T1 (sl) 2015-06-30
EP2503338B1 (en) 2014-12-24
KR20160029869A (ko) 2016-03-15
US20100209942A1 (en) 2010-08-19
HRP20150181T1 (hr) 2015-06-19
ES2532361T3 (es) 2015-03-26
EP2503338A2 (en) 2012-09-26
HRP20120743T1 (hr) 2012-10-31
PL2503338T3 (pl) 2015-06-30
SI2201376T1 (sl) 2012-09-28
EP2201376A4 (en) 2011-03-23
FI20070795A0 (fi) 2007-10-24
DK2201376T3 (da) 2012-10-15
JP5619810B2 (ja) 2014-11-05
WO2009053523A1 (en) 2009-04-30
CA2702635A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
CY1116089T1 (el) Cd73 ως ενας βιοδεικτης για την παρακολουθηση της εξελιξης νοσων και εκτιμηση της αποτελεσματικοτητας θεραπειων
EA201100965A1 (ru) Биомаркеры для ингибиторов с антиангиогенной активностью
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
BR112015011359A8 (pt) método para indicar uma presença ou não presença de câncer de próstata agressivo, dispositivo de ensaio, kit de teste, produto de programa de computador, e aparelho
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
DK1421215T3 (da) Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA
EP1913391A4 (en) QUANTITATIVE ASSAYS FOR PDGFR IN BODY FLUIDS
CY1118377T1 (el) Syk αναστολεις ιμιδαζοπυραζινης
BRPI0906683B8 (pt) método para medir e caracterizar microvesículas em fluidos corporais humanos
BR112014002975A2 (pt) composições de biomarcador e métodos
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
CY1117817T1 (el) Υποκατεστημενα ακυλανιλιδια και μεθοδοι χρησης αυτων
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes
JOP20190199B1 (ar) استخدام العوامل الحيوية في تحديد مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط prmt5
CY1115640T1 (el) Διαγνωση και αγωγη εναντι της σχιζοφρενειας
ATE531820T1 (de) Gesundheitszustandstest
CY1125388T1 (el) Πολυπλεγμενη παραλληλη αναλυση εμπλουτισμενη σε στοχους για την αξιολογηση βιοδεικτων ογκου
CY1122202T1 (el) Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης
EP4502182A3 (en) Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra)
MX377026B (es) Biomarcadores para la progresión de enfermedades en melanoma.
BR112015021507A2 (pt) métodos e composições para o diagnóstico de pré-eclampsia
EP2245460A4 (en) TEST SYSTEM FOR ASSESSING ONCOGENICITY, TUMOR DEVELOPMENT AND EFFICACY OF TREATMENT
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie